Why the study?
Patients with autoimmune rheumatic diseases exhibit heightened systemic inflammation and increased cardiovascular risk, with emerging data linking perivascular adipose tissue to cardiovascular disease pathogenesis.
How does perivascular adipose tissue (PVAT) contribute to the pathogenesis of cardiovascular disease in patients with autoimmune rheumatic diseases, and what is the role of PVAT imaging?
How does perivascular adipose tissue (PVAT) contribute to the pathogenesis of cardiovascular disease in patients with autoimmune rheumatic diseases, and what is the role of PVAT imaging?
Answers are grounded in this paper and cite their sources.
Dysfunctional perivascular adipose tissue may play a key role in the increased cardiovascular risk seen in patients with autoimmune rheumatic diseases, and novel imaging techniques can help assess this risk.
Perivascular adipose tissue (PVAT) resides at the outermost boundary of the vascular wall, surrounding most conduit blood vessels, except for the cerebral vessels, in humans. A growing body of evidence suggests that inflammation localized within PVAT may contribute to the pathogenesis of cardiovascular disease (CVD). Patients with autoimmune rheumatic diseases (ARDs), e.g., systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), psoriasis, etc., exhibit heightened systemic inflammation and are at increased risk for CVD. Data from clinical studies in patients with ARDs support a linkage between dysfunctional adipose tissue, and PVAT in particular, in disease pathogenesis. Here, we review the data linking PVAT to the pathogenesis of CVD in patients with ARDs, focusing on the role of novel PVAT imaging techniques in defining disease risk and responses to biological therapies.
No takes yet. Share an insight, caveat, or question.
Shi et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: